Ashton Thomas Private Wealth LLC Raises Stock Position in Cencora, Inc. (NYSE:COR)

Ashton Thomas Private Wealth LLC lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 7.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,508 shares of the company’s stock after buying an additional 398 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in Cencora were worth $1,237,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the stock. Callan Family Office LLC lifted its position in shares of Cencora by 602.6% during the 4th quarter. Callan Family Office LLC now owns 12,070 shares of the company’s stock worth $2,712,000 after buying an additional 10,352 shares during the last quarter. E Fund Management Co. Ltd. increased its holdings in shares of Cencora by 81.3% in the 4th quarter. E Fund Management Co. Ltd. now owns 1,820 shares of the company’s stock valued at $409,000 after acquiring an additional 816 shares during the period. Candriam S.C.A. increased its holdings in shares of Cencora by 2.2% in the 4th quarter. Candriam S.C.A. now owns 8,040 shares of the company’s stock valued at $1,806,000 after acquiring an additional 176 shares during the period. Freestone Capital Holdings LLC increased its holdings in shares of Cencora by 0.8% in the 4th quarter. Freestone Capital Holdings LLC now owns 31,967 shares of the company’s stock valued at $7,183,000 after acquiring an additional 253 shares during the period. Finally, Lindbrook Capital LLC increased its holdings in shares of Cencora by 24.5% in the 4th quarter. Lindbrook Capital LLC now owns 661 shares of the company’s stock valued at $149,000 after acquiring an additional 130 shares during the period. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In related news, CEO Robert P. Mauch sold 4,970 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $255.00, for a total value of $1,267,350.00. Following the sale, the chief executive officer now directly owns 51,070 shares in the company, valued at $13,022,850. The trade was a 8.87 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,648 shares of company stock valued at $2,862,342 in the last ninety days. 10.80% of the stock is currently owned by company insiders.

Cencora Stock Performance

NYSE:COR opened at $254.54 on Monday. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26. The stock has a market cap of $49.36 billion, a PE ratio of 36.21, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The firm’s fifty day simple moving average is $244.34 and its 200-day simple moving average is $238.39.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Stockholders of record on Friday, February 14th were paid a dividend of $0.55 per share. The ex-dividend date was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.86%. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on COR. StockNews.com cut shares of Cencora from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Mizuho began coverage on shares of Cencora in a report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 target price on the stock. Evercore ISI lifted their target price on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Finally, Wells Fargo & Company boosted their price objective on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research note on Wednesday, January 29th. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $277.90.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.